Visani, Giuseppe <br/><br/>
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.  [electronic resource] 

 -  Blood  Sep 2011 
 - 3419-25 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2011-04-351924  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bendamustine Hydrochloride<br/>Cytarabine--administration & dosage<br/>Drug Resistance, Neoplasm<br/>Etoposide--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Graft Survival<br/>Hematopoietic Stem Cell Transplantation<br/>Hodgkin Disease--immunology<br/>Humans<br/>Lymphoma, Non-Hodgkin--immunology<br/>Male<br/>Melphalan--administration & dosage<br/>Middle Aged<br/>Nitrogen Mustard Compounds--administration & dosage<br/>Recurrence<br/>Remission Induction<br/>Salvage Therapy--methods<br/>Transplantation Conditioning--methods<br/>Transplantation, Autologous